WO2004011498A3 - Long lasting natriuretic peptide derivatives - Google Patents

Long lasting natriuretic peptide derivatives Download PDF

Info

Publication number
WO2004011498A3
WO2004011498A3 PCT/CA2003/001097 CA0301097W WO2004011498A3 WO 2004011498 A3 WO2004011498 A3 WO 2004011498A3 CA 0301097 W CA0301097 W CA 0301097W WO 2004011498 A3 WO2004011498 A3 WO 2004011498A3
Authority
WO
WIPO (PCT)
Prior art keywords
long lasting
natriuretic peptide
peptide derivatives
peptide
derivatives
Prior art date
Application number
PCT/CA2003/001097
Other languages
French (fr)
Other versions
WO2004011498A2 (en
Inventor
Dominique P Bridon
Peter Bakis
Julie Carette
France Leclaire
Roger Leger
Martin Robitaille
Original Assignee
Conjuchem Inc
Dominique P Bridon
Peter Bakis
Julie Carette
France Leclaire
Roger Leger
Martin Robitaille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002488348A priority Critical patent/CA2488348A1/en
Priority to JP2004523679A priority patent/JP2006514607A/en
Priority to US10/471,348 priority patent/US20040266673A1/en
Priority to EP03771007A priority patent/EP1530588A2/en
Priority to AU2003246500A priority patent/AU2003246500A1/en
Application filed by Conjuchem Inc, Dominique P Bridon, Peter Bakis, Julie Carette, France Leclaire, Roger Leger, Martin Robitaille filed Critical Conjuchem Inc
Publication of WO2004011498A2 publication Critical patent/WO2004011498A2/en
Publication of WO2004011498A3 publication Critical patent/WO2004011498A3/en
Priority to US11/040,810 priority patent/US20050176641A1/en
Priority to US11/067,556 priority patent/US7601691B2/en
Priority to US11/923,222 priority patent/US7906482B2/en
Priority to US11/926,843 priority patent/US20080199532A1/en
Priority to US12/253,856 priority patent/US20090275506A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

This invention relates to long lasting natriuretic peptide (NP) derivatives. The NP derivative has a NP peptide and a reactive entity coupled to the NP peptide. The reactive entity is able to covalently bond with a functionality on a blood component. In particular, this invention relates to NP derivatives having an extended in vivo half-life, and method for the treatment of cardio-vascular diseases and disorders such as acute decompensated congestive heart failure (CHF) and chronic CHF.
PCT/CA2003/001097 1999-05-17 2003-07-29 Long lasting natriuretic peptide derivatives WO2004011498A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002488348A CA2488348A1 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives
JP2004523679A JP2006514607A (en) 2002-07-31 2003-07-29 Long-lasting sodium excretion increasing peptide derivative
US10/471,348 US20040266673A1 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives
EP03771007A EP1530588A2 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives
AU2003246500A AU2003246500A1 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives
US11/040,810 US20050176641A1 (en) 2000-05-17 2005-01-21 Long lasting natriuretic peptide derivatives
US11/067,556 US7601691B2 (en) 1999-05-17 2005-02-25 Anti-obesity agents
US11/923,222 US7906482B2 (en) 1999-05-17 2007-10-24 Anti-obesity agents
US11/926,843 US20080199532A1 (en) 1999-05-17 2007-10-29 Long Lasting Natriuretic Peptide Derivatives
US12/253,856 US20090275506A1 (en) 2000-05-17 2008-10-17 Long lasting natriuretic peptide derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40041302P 2002-07-31 2002-07-31
US40019902P 2002-07-31 2002-07-31
US60/400,199 2002-07-31
US60/400,413 2002-07-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/471,348 A-371-Of-International US20040266673A1 (en) 1999-05-17 2003-07-29 Long lasting natriuretic peptide derivatives
US11/040,810 Continuation US20050176641A1 (en) 1999-05-17 2005-01-21 Long lasting natriuretic peptide derivatives

Publications (2)

Publication Number Publication Date
WO2004011498A2 WO2004011498A2 (en) 2004-02-05
WO2004011498A3 true WO2004011498A3 (en) 2004-06-24

Family

ID=31191354

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001097 WO2004011498A2 (en) 1999-05-17 2003-07-29 Long lasting natriuretic peptide derivatives

Country Status (5)

Country Link
EP (1) EP1530588A2 (en)
JP (2) JP2006514607A (en)
AU (1) AU2003246500A1 (en)
CA (1) CA2488348A1 (en)
WO (1) WO2004011498A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662773B2 (en) 2002-11-26 2010-02-16 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US7112567B2 (en) 2001-02-16 2006-09-26 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
CA2559853A1 (en) 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
EP2348114B1 (en) 2004-04-21 2018-07-25 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
WO2006005140A2 (en) 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
MX2007010930A (en) * 2005-03-07 2008-03-14 Mondobiotech Licensing Out Ag Formulation for aviptadil.
WO2006108686A2 (en) * 2005-04-14 2006-10-19 Aic Bnp agonists
WO2007041645A2 (en) * 2005-10-03 2007-04-12 Scios Inc. Oxidized human bnp
CA2656990A1 (en) 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
JP5010913B2 (en) * 2006-12-31 2012-08-29 寿子 小出 Tissue regeneration preparation containing atrial diuretic hormone family molecule as active substance, tissue regeneration method using the preparation, hair growth, hair growth, hair restorer and skin tissue repair improving agent containing atrial diuretic hormone family molecule as active substance Hair growth, hair thickening, hair growth promoting method and skin tissue repair improving method using the preparation
KR20080098216A (en) * 2007-05-04 2008-11-07 한미약품 주식회사 Natriuretic peptide conjugate using carrier substance
EP2162464A1 (en) * 2007-06-06 2010-03-17 Boehringer Ingelheim International GmbH Natriuretic fusion proteins
WO2009006732A1 (en) * 2007-07-06 2009-01-15 Theratechnologies Inc. Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury
DE102010032482A1 (en) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen New receptor agonist having renin-suppressing activity, antihypertrophic activity and influence of second messenger cyclic guanosine monophosphate during vasodilation, natriuresis and diuresis, useful to treat e.g. nephrotic syndrome
WO2012013597A1 (en) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Substances and the use thereof for influencing natriuretic peptide receptors
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CN103402534B (en) * 2011-02-23 2016-10-12 麦德林制药私人有限公司 For treating the Therapeutic Method of congestive heart failure
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
CN102286092B (en) 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 Solid-phase synthesis method of liraglutide
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3226891A1 (en) 2014-12-05 2017-10-11 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016272282A1 (en) * 2015-05-29 2018-01-25 Igisu Co., Ltd. Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (en) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Identifying effective dosing regimens for tissue-nonspecific alkaline phosphatase (TNSALP) enzyme replacement therapy for hypophosphataseemia
JP2018533571A (en) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods for treating cranial suture early healing disease in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
CN116284329B (en) * 2023-04-28 2023-12-08 成都奥达生物科技有限公司 Long-acting natriuretic peptide compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE862891L (en) * 1985-11-05 1987-05-05 Behringwerke Ag Analogs of atrial natriuretic peptides
JP3042782B2 (en) * 1985-11-05 2000-05-22 サイオス インコーポレイテッド Atrial natriuretic peptide-enhancing compound
EP0431113A4 (en) * 1989-05-24 1992-01-22 Abbott Laboratories Atrial peptide derivatives
JP4209086B2 (en) * 1999-05-17 2009-01-14 コンジュケム バイオテクノロジーズ インコーポレイテッド Long-lasting anti-angiogenic peptide
JP2003508502A (en) * 1999-09-07 2003-03-04 コンジュケム，インコーポレーテッド Methods and compositions for the production of long-lasting antineoplastic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEGER ROGER ET AL: "Synthesis and in vitro analysis of atrial natriuretic peptide-albumin conjugates.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 20, 20 October 2003 (2003-10-20), pages 3571 - 3575, XP001156881, ISSN: 0960-894X *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662773B2 (en) 2002-11-26 2010-02-16 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9289507B2 (en) 2012-05-17 2016-03-22 Extend Biosciences, Inc. Carriers for improved drug delivery
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates

Also Published As

Publication number Publication date
CA2488348A1 (en) 2004-02-05
EP1530588A2 (en) 2005-05-18
JP2006514607A (en) 2006-05-11
AU2003246500A1 (en) 2004-02-16
WO2004011498A2 (en) 2004-02-05
JP2010047614A (en) 2010-03-04

Similar Documents

Publication Publication Date Title
WO2004011498A3 (en) Long lasting natriuretic peptide derivatives
WO2004020410A3 (en) Dihydropyridinone derivatives as hne inhibitors
EP1408038A3 (en) Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
EP1623994A3 (en) Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU2003210210A1 (en) The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
WO2001037850A3 (en) Use of a milk protein hydrolysate in the treatment of diabetes
AU2002331563A1 (en) Physiological heart pump control
AU2001251514A1 (en) Method for detecting cheyne-stokes respiration in patients with congestive heart failure
WO2002060389A3 (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
WO2000074666A3 (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
WO2002047716A3 (en) Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002234207A1 (en) Low profile pivoting joint infusion assembly
WO2003096977A3 (en) Methods of treating hepatitis
EP1534358B8 (en) Low profile inlet for an implantable blood pump
AU2003214214A1 (en) Method for treating congestive heart failure
WO2004075852A3 (en) Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
WO2003092541A3 (en) Hardenable orthopaedic supports
AU2003260491A1 (en) Vascular prosthesis, especially for replacing the ascending aorta
WO2004110738A3 (en) Interlocking tooth bond for assembly of fiber composite laminates
WO2001091826A3 (en) Cannula assembly for medical applications and method of manufacture
AU2003268218A1 (en) Flexible composite guidewire for intravascular catheter
AU2003257187A1 (en) Dialysis catheters with optimized user-friendly connections
EP1300084A3 (en) Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves
WO2008150565A3 (en) Ranolazine for elevated brain-type natriuretic peptide
WO2002044113A3 (en) Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10471348

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2488348

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003246500

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003771007

Country of ref document: EP

Ref document number: 2004523679

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003771007

Country of ref document: EP